Advertisements

Дексаметазон-Виал

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Дексаметазон-Виал

Property Description
Active ingredient Dexamethasone
Form Sterile solution for injection
Pharmacological class Glucocorticoid (Corticosteroid)
General purpose Anti-inflammatory and Immunosuppressive
Origin Synthetic (Fluorinated steroid)

What Type of Medicine is Дексаметазон-Виал? (Definition and Classification)

Дексаметазон-Виал is a medicinal product containing Dexamethasone, a highly potent synthetic compound that belongs to the Glucocorticoid pharmacological class, which is a subdivision of Corticosteroids. This class of medicines is engineered to mimic and significantly enhance the actions of cortisol, a natural steroid hormone, providing powerful therapeutic effects. As a specific fluorinated steroid, Dexamethasone is clinically recognized for its high potency and long duration of action compared to many shorter-acting analogues.

Composition, Origin, and Dosage Form

The active component in this preparation is typically Dexamethasone sodium phosphate, which is the water-soluble ester salt of the main compound. Дексаметазон-Виал is formulated as a sterile solution intended for parenteral delivery, which means it is administered via injection, ensuring quick and systemic availability of the drug. The product is defined as a single-component product dissolved in an aqueous solution. The selection of the highly soluble sodium phosphate salt is a key formulation feature, specifically intended to allow rapid action following injection, which is essential in acute care settings.

General Purpose: Anti-inflammatory and Immunosuppressive Action

The general purpose of this medication is to rapidly suppress and manage conditions characterized by intense, harmful bodily inflammation and to stabilize situations where the immune system is excessively active. Dexamethasone functions powerfully to decrease the body's natural defense responses. This drug’s role includes controlling severe, inappropriate immune activity, such as the reduction of profound swelling. Dexamethasone acts as a potent anti-inflammatory agent and a powerful immunosuppressive agent, protecting tissues from damage caused by severe allergic reactions or widespread inflammatory responses.

Regulatory References

  1. Dexamethasone - StatPearls - NCBI Bookshelf
Advertisements

What side effects are possible with Дексаметазон-Виал?

Possible side effects and safety information

The safety profile for this medication, containing the glucocorticoid Dexamethasone, is officially structured by regulatory bodies to detail adverse reactions and safety considerations. The range of potential effects is systematically categorized by the System-Organ Class (SOC) they affect, recognizing that the risk profile is significantly influenced by the dose and duration of systemic exposure.

Adverse Reaction Scope and Classification

Adverse reactions are documented across several physiological systems. Common effects, reported in official labeling, include metabolic changes such as weight gain, fluid retention, and impaired glucose tolerance, alongside psychiatric disturbances like mood swings and insomnia. Endocrine disorders, notably the suppression of the Hypothalamic-Pituitary-Adrenal (HPA) axis, are classified as Very Common (ge 1/10) with prolonged systemic use.

System-Organ Class Examples of Documented Effects
Musculoskeletal Osteoporosis, myopathy, avascular necrosis (uncommon/rare)
Gastrointestinal Peptic ulceration, pancreatitis, hemorrhage
Ophthalmic Posterior subcapsular cataracts, glaucoma

Serious Safety Considerations

Official documents list several clinically significant events. The risk of Acute Adrenocortical Insufficiency is explicitly documented upon the abrupt cessation of prolonged therapy. Other serious reactions include severe gastrointestinal perforation and certain psychotic manifestations. A safety constraint is the general restriction against use in patients with active systemic fungal infections.

Population-Specific Notes

Specific safety considerations are noted for certain groups. For the paediatric population, monitoring for growth retardation is required. Older adults may face an increased risk of common side effects, including osteoporosis and hypertension, according to official regulatory data.

Advertisements

Overdose and Emergency Response

The official regulatory documentation for excessive systemic exposure to the active substance, Dexamethasone, defines the potential overdose profile based on documented physiological findings. These manifestations primarily involve the cardiovascular system and fluid/electrolyte balance, characterized by the elevation of blood pressure (hypertension) and disturbances such as salt and water retention. Excessive exposure also causes an increased excretion of potassium, leading to hypokalemia.

Overdose may lead to severe systemic outcomes requiring urgent action. These documented risks include convulsions and congestive heart failure, particularly in susceptible patients. Immediate medical attention is required for any suspected excessive use or the acute onset of these severe manifestations.

Since no specific antidote is known, the management approach described in the official label is strictly symptomatic and supportive. Regulatory guidance mandates close monitoring of fluid and electrolyte status and blood pressure monitoring. Specific supportive measures documented for managing the resulting imbalances include dietary salt restriction and necessary potassium supplementation.

Advertisements

Therapeutic Uses of Дексаметазон-Виал

The primary therapeutic role of Dexamethasone is to offer supportive symptomatic relief in clinical situations marked by severe inflammation and excessive immune activity. This medication is commonly used across conditions presenting with acute episodes to ease symptoms that create noticeable physiological strain and interfere with daily functioning.


This treatment is generally applied in addressing symptoms associated with acute or episodic changes, including those seen in conditions such as severe allergic reactions, swelling of the brain (cerebral edema), exacerbations of asthma and COPD, and flares of systemic autoimmune diseases like lupus and rheumatoid arthritis. This usage is relevant when supportive symptom management is appropriate and symptoms create noticeable physiological strain.

“The goal is providing symptomatic support that helps ease the overall symptom burden during episodes of heightened symptoms.”


Quick Fact: Relief for Localized Swelling

This medication may assist with maintaining functional stability by addressing symptoms related to localized swelling, applied in contexts involving significant discomfort, such as swelling in the larynx or brain.

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Eligibility for Дексаметазон-Виал is strictly determined by regulatory labeling, which outlines populations who can and cannot use the medicine.

Regulatory documents state the medicine is contraindicated and must not be used by patients with systemic fungal infections or those with a known hypersensitivity to dexamethasone or its components. Regulators also warn against use in patients with certain active viral diseases, such as active herpes or varicella. Furthermore, eligibility is dependent on excluding or treating pre-existing parasitic conditions, specifically amebiasis and Strongyloidiasis, prior to treatment initiation.

Use is restricted and requires increased caution and clinical monitoring for individuals with comorbidities, including Diabetes Mellitus, uncontrolled Hypertension, Congestive Heart Failure, and a history of peptic ulcers. Patients with Hepatic or Renal Impairment also require careful monitoring.

Special restrictions apply to specific populations. The label advises against breastfeeding for mothers receiving high pharmacological doses. In pregnancy, use is restricted to cases where the benefits demonstrably outweigh the potential risks to the fetus. For pediatric patients, long-term use requires mandatory, regular growth checks to monitor for growth inhibition.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions with this drug are officially documented across several domains, requiring clinical awareness and monitoring.

Interacting Product Category Key Practical Implication (Official Statement)
Strong CYP3A4 Inhibitors (e.g., Ketoconazole) May decrease the drug’s metabolism, leading to increased plasma concentrations and a potential for enhanced effects. Official regulatory advice is to avoid concomitant use.
Strong CYP3A4 Inducers (e.g., Phenytoin, Rifampicin, Barbiturates) May increase the drug’s metabolism and clearance, leading to decreased plasma concentrations and reduced therapeutic effectiveness. Official regulatory advice is to avoid concomitant use.
Oral Anticoagulants (e.g., Warfarin) May result in either an enhanced or a diminished anticoagulant effect due to altered metabolism or protein binding. Coagulation tests (e.g., INR/PT) require monitoring during co-administration.
Antidiabetic Agents (e.g., Insulin, Sulfonylureas) The drug can increase blood glucose levels, which may necessitate an adjustment in the dose of the antidiabetic medication to maintain glucose control.
NSAIDs and Aspirin Use with these products may increase the risk of gastrointestinal irritation, ulceration, and hemorrhage due to cumulative gastrointestinal toxicity.
Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) May enhance the risk of hypokalemia (low potassium), which requires monitoring. Use with Amphotericin B has been associated with an increased risk of cardiac complications.
Live or Live Attenuated Vaccines Administration is restricted in individuals receiving immunosuppressive doses of this drug.

These interactions are categorized by regulatory bodies based on the mechanism, primarily involving hepatic enzyme metabolism and pharmacodynamic effects on glucose, electrolytes, and the gastrointestinal tract. Official documentation dictates that these combinations are either restricted, require close monitoring, or may necessitate a dose adjustment of the co-administered medication.

Advertisements

Mechanism of Action

The mechanism of action for Dexamethasone is initiated by its high-affinity interaction with the Cytosolic Glucocorticoid Receptor ( GR), the primary molecular target within cells. The drug acts as an agonist, forming a complex that translocates into the cell nucleus, where it modulates gene transcription.

Intracellular Receptor Agonism and Gene Control

This binding event modifies which genes are expressed, primarily through transrepression and transactivation, thereby controlling cellular output. The drug inhibits key inflammatory pathways by suppressing pro-inflammatory transcription factors, such as NF-kappa B. This intervention prevents the synthesis of major inflammatory mediators, including cytokines and chemokines.

️ Suppression of Pro-Inflammatory Cascades

The mechanism also involves indirectly blocking the arachidonic acid cascade by promoting the synthesis of Annexin A1, which inhibits the PLA2 enzyme. This action prevents the production of prostaglandins and leukotrienes. These cellular changes result in the physiological consequence of reduced capillary permeability and decreased immune cell migration.

️ Systemic Metabolic and Immunological Modulation

Beyond localized effects, Dexamethasone modulates systemic processes by suppressing the function of immune cells ( T-lymphocytes, macrophages) and engaging in metabolic modulation. It promotes the genes necessary for increased glucose production ( gluconeogenesis), resulting in the modulation of systemic immune and metabolic homeostasis.

Advertisements

Dosage and Administration Information

The administration of Дексаметазон-Виал (Dexamethasone sodium phosphate injection) involves specific parameters regarding the route, dosing, and procedural handling of the sterile solution.

Administration Scope

Property Instruction
Route of administration The product is administered via Intravenous (IV) or Intramuscular (IM) injection. Administration may also include local injections, such as intra-articular (into joints), intralesional, and soft tissue infiltration.
Dosing schedule (Adults) Systemic dosage is individualized, commonly ranging from 0.5 mg to 9.0 mg daily. For severe, acute conditions (e.g., cerebral edema), a higher initial dose of 10 mg IV is often followed by 4 mg IM or IV every 6 hours.
Frequency pattern The medicine is administered once daily or in divided doses (e.g., every 6 hours), with frequency determined by the acuteness of the condition and the required level of drug exposure.
Age-group administration rules Pediatric dosing is typically based on body weight or surface area, with dose ranges such as 0.02 mg/kg to 0.3 mg/kg per 24 hours in divided doses, and is individualized according to clinical requirements.

Preparation and Procedural Conditions

Property Instruction
Preparation requirements The sterile solution should be visually inspected for discoloration or particulate matter before use. It may be administered undiluted or diluted with specific approved intravenous solutions (e.g., Sodium Chloride 0.9% or Glucose 5%) for infusion.
Special procedural conditions Intravenous injections, particularly of larger doses, must be administered slowly over a period of several minutes. Furthermore, strict aseptic conditions must be maintained for all local injections.
Tapering and Duration Following prolonged use (e.g., beyond three weeks) or when discontinuing high-dose therapy, the dose must be gradually reduced (tapered) to allow the body's natural physiological function to recover.

Connection to the Administration Protocol

These parameters define a protocol for administration that requires parenteral delivery via specific routes (IV, IM, local). The process involves adherence to individualized dosage ranges and a gradual tapering process upon discontinuation after long-term or high-dose courses. This structured approach to use includes specific requirements for dilution and the speed of administration.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Дексаметазон-Виал

The clinical evaluation of Дексаметазон-Виал (Dexamethasone) involves extensive research focused on its use during acute, episodic events characterized by high levels of inflammation and immune system activity. Studies conducted globally use design frameworks like randomized controlled trials (RCTs) and systematic reviews to examine how the medicine was observed in specific clinical scenarios. Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.


Evidence for Acute, Life-Threatening Inflammatory Conditions

Severe Hypoxemic Respiratory Illness (e.g., COVID-19)

Research examined patients hospitalized with severe low blood oxygen levels (hypoxemia) who required respiratory support. Large-scale randomized controlled trials and systematic reviews monitored critical outcomes, including evaluation of survival-related outcomes (at 28 days and up to 180 days), the need for mechanical ventilation, and length of hospital stay. Findings describe patterns observed in these studies related to evaluation of survival-related outcomes compared to standard care or placebo. Research highlights that these measured changes may be primarily applicable in the subgroup of patients receiving mechanical ventilation. Long-term outcomes are not well characterized.

Acute Respiratory Distress Syndrome (ARDS)

Research examined the use of the medicine in individuals diagnosed with Acute Respiratory Distress Syndrome. Studies explored evaluation of survival-related outcomes and evaluation of time spent on mechanical ventilation. Findings describing patterns related to evaluation of time spent on mechanical ventilation were reported in studies compared to control groups.


Evidence for Acute Symptom Management

Postoperative Pain and Nausea

The medicine was evaluated in short-term randomized controlled trials for adult patients undergoing surgical procedures. These trials assessed outcomes related to physical discomfort, specifically monitoring evaluation of pain intensity scores and evaluation of reported usage of opioid pain relievers. The evidence is limited regarding the specific impact study of the medicine may have on post-surgical wound healing metrics.

Acute Asthma in Children

Research examined the use of the medicine in the pediatric population presenting with acute asthma attacks. Studies explored evaluation of the frequency of unscheduled follow-up healthcare visits and evaluation of time until symptom resolution when compared to other steroid courses. Results apply only to the pediatric populations studied. Long-term outcomes are not well characterized for this use.


Research Gaps and Uncertainty

Key research gaps include the need for more comparative evidence to determine the optimal dose or duration of treatment. Data for non-hospitalized individuals and certain physiological populations remain insufficient. Follow-up durations were limited in most short-term symptom studies. Evidence quality varies across studies, especially when assessing specific subgroups, indicating that subgroup findings are uncertain and warrant further research.

Key Studies & References

  1. NIH MedlinePlus Drug Information: Dexamethasone Injection
  2. Dexamethasone to prevent postoperative nausea and vomiting: a meta-analysis of randomized controlled trials
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Дексаметазон-Виал (FAQ)

Q: How does this injection differ from dexamethasone tablets or eye drops in its general function?

The core function of the drug, which is to act as a potent glucocorticoid (a type of steroid), remains consistent across all forms. However, the injectable solution is specifically formulated for delivery via injection (parenteral administration), ensuring rapid systemic availability. This difference relates to the route of administration and the intended timeframe for the drug to become systemically available.

Q: What kind of conditions is Дексаметазон-Виал generally used to manage?

Official labeling indicates that Dexamethasone is approved for use in various disorders. These include replacement therapy for adrenocortical insufficiency, severe allergic and inflammatory conditions, certain blood and rheumatic diseases, and specific respiratory disorders. It is also indicated for use in cases of cerebral edema (brain swelling) and certain neoplastic states.

Q: Does Дексаметазон-Виал treat the cause of a disease or only the symptoms, according to official information?

Official information indicates that Dexamethasone, as a glucocorticoid, primarily functions to suppress and manage symptoms related to severe inflammation and an overactive immune response. This mechanism controls the body’s reaction to the disease rather than correcting the underlying cause of the original illness.

Q: Is 'moon face' a known potential physical change from using this drug?

Yes, regulatory information documents that 'moon face' (a puffy or rounded appearance of the face), alongside general weight gain, is a potential physical change. This is listed as a serious side effect and can be a sign of Cushing's syndrome, which is associated with prolonged systemic exposure.

Q: Is a temporary increase in appetite a possibility when receiving this medication?

Yes, an increase in appetite is listed in official product information as a commonly reported side effect. This change is related to the drug's documented effect on metabolic processes in the body.

Q: Is it true that this medicine can make a person more susceptible to infections?

Official regulatory warnings confirm that the medication has immunosuppressive properties. This action can increase a person's vulnerability to developing new infections and may also mask the typical signs and symptoms of an infection already present.

Q: What symptoms are described in regulatory documents as signs of potential adrenal gland issues?

Signs of potential adrenal gland issues, particularly acute adrenocortical insufficiency, include low blood pressure, severe fatigue, loss of appetite, upset stomach, and vomiting. These symptoms are important information noted in the regulatory warnings.

Q: Can a single dose of the injection cause any temporary side effects?

Temporary side effects can occur even with short-term or single-dose use, according to general safety data. Commonly reported transient effects include difficulty sleeping (insomnia), mild stomach upset, headache, and mood changes.

Q: Why do some people experience muscle weakness or cramps while on this type of medication?

The regulatory safety data lists muscle weakness (myopathy) as a potential side effect. Additionally, the drug may lead to low potassium levels (hypokalemia), which can be a cause of muscle pain and cramps. These effects are associated with the drug’s potential impact on the musculoskeletal system and electrolyte balance.

Q: Are there any known dermatological effects like skin thinning or bruising from steroid use?

Yes, official labeling notes that prolonged use of Dexamethasone can lead to certain skin changes. Documented dermatological effects include skin thinning (fragility), easy bruising, stretch marks, and acne.

Q: What are the signs of withdrawal symptoms described for patients who stop taking the drug?

If the dose is not gradually reduced after long-term use, withdrawal symptoms linked to acute adrenal insufficiency may occur. These signs include fever, joint and muscle pain, peeling skin, headache, significant loss of appetite, and severe fatigue.

Q: Is there a described connection between Dexamethasone and high blood pressure?

Yes, official safety information indicates that Dexamethasone may cause or worsen high blood pressure (hypertension) and fluid retention in some patients. Official labeling notes that pre-existing high blood pressure is a condition that requires careful clinical consideration during treatment.

Q: Is alcohol use generally restricted or advised against while taking this medication?

Official drug warnings indicate that consumption of alcoholic beverages should be limited or avoided during treatment. This is because the drug increases the gastrointestinal tract’s susceptibility to irritation, and combining it with alcohol may increase the risk of stomach ulcers or hemorrhage.

Q: What is the typical timeframe for the onset of the drug's anti-inflammatory action?

The injection form is designed for rapid systemic availability. Regulatory and pharmacokinetic data indicate that the anti-inflammatory effects typically have an onset of action within 1 to 2 hours following administration.

Q: How long does the effect of a single injection generally last in the body?

Dexamethasone is classified as a long-acting corticosteroid. The biological effects following a single dose are generally described as persisting for 36 to 54 hours, and in some situations, the effect may last for several days.

Q: How long does Dexamethasone remain detectable in a person's system?

Based on pharmacokinetic data, the average terminal half-life of the drug in adults is about 4 hours. This indicates that most of the drug is generally eliminated from the system within about 20 hours, although the precise elimination time can vary based on individual physiological factors.

Q: Is it common for the dose to be adjusted based on a patient's individual response?

Official prescribing guidelines emphasize that systemic dosage is highly individualized. The dose is determined and may be adjusted based on the severity of the specific condition and the patient’s clinical response, as mandated by official prescribing guidelines.

Q: Is it possible to drive or operate machinery while using this medication?

Official information indicates that caution is necessary regarding driving or operating machinery. This is due to the potential for certain side effects, such as visual disturbances, confusion, and mood changes, which may impair abilities.

Q: What is the official recommendation regarding contact with people who have chickenpox or measles?

Official guidance highlights that individuals receiving immunosuppressive doses need to minimize or avoid exposure to people with chickenpox or measles. Exposure requires medical consultation, as the suppressed immune system increases the risk of developing a serious illness from these viruses.

Q: Is there information on whether the medicine affects hormonal contraception?

Regulatory documents indicate that Dexamethasone may reduce the blood levels and effectiveness of some hormonal contraceptives. The potential effect may include an increased risk of breakthrough bleeding. It is noted that the effectiveness of hormonal contraceptives may be reduced.

Q: Why is Dexamethasone sometimes used in diagnostic tests, according to medical literature?

The medication is used in specific diagnostic procedures, such as the Dexamethasone Suppression Test. This test uses the drug to help check for conditions like Cushing's syndrome by measuring how it interacts with and suppresses the body’s natural cortisol levels.

Advertisements

How should Дексаметазон-Виал be stored and disposed of?

How to Store and Dispose of Dexamethasone Injection

Storage and disposal must strictly follow the requirements documented in official regulatory labeling to ensure product stability and safety.

Official Storage Conditions

Dexamethasone Sodium Phosphate Injection must be stored at Controlled Room Temperature, defined as 20° to 25°C (68° to 77°F). It is mandatory to protect the solution from light and it must not be exposed to freezing temperatures. The product must be kept in its original, tightly closed, light-resistant container.

Storage Restriction Requirement
Temperature Controlled Room Temperature (20° to 25°C)
Protection Must be protected from light and freezing
Child Safety Store out of the sight and reach of children

Disposal Requirements

Unused or expired medicine and the container must be disposed of in accordance with local, regional, and national regulations. To protect the environment, disposal should be done via an approved waste disposal process, and release into sewers or water courses is prohibited.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Дексаметазон-Виал found in:

A-Z Index: